# TPB earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TPB) · [Earnings tab](https://www.lopjlb.com/stock/TPB?tab=earnings)

Updated: 2026-11-09T03:22:06

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards, TPB’s narrative shifted from modest guidance adjustments and vague uncertainty in late‑2024 to increasingly confident outlooks anchored by explosive Modern Oral growth. Management tone rose from neutral in Q3 2024 to consistently positive by Q2 2025, reflecting strong white nicotine‑pouch demand that repeatedly outpaced guidance (8‑10x YoY). EBITDA guidance climbed from $101‑103 M FY24 to $115‑120 M FY25 and $70‑90 M FY26, while margin pressure from mix shifts was noted early but began to ease as gross margins improved (57.1% in Q2 2025). Capital deployment accelerated: sales‑force doubling, US manufacturing on‑shoring, and extensive brand launches (Free, Out, Zig‑Zag extensions). Regulatory and competitive fears surfaced in Q4 2024 and persisted through Q1 2025, but later calls omitted new concerns, suggesting resolution or de‑prioritisation. Tariff exposure was highlighted in Q1 2025 and mitigated by inventory and price actions by Q2 2025. Distribution milestones (7‑Eleven partnership, ALP brick‑and‑mortar rollout) moved from on‑track to delivered, underscoring expanding retail reach. Overall, the company transitioned from cautious guidance to aggressive growth targets driven by Modern Oral momentum and operational scaling.

## Latest CallCard · Q2

TPB delivered strong Modern Oral growth (gross sales +149% YoY), raised Modern Oral guidance, maintained EBITDA guidance, and continues investing in sales force, US manufacturing, and PMTA progress amid shelf reset lead times.','tone':{'mgmt':0.5,'mgmt_rationale':'Management highlights strong execut

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** TPB delivered strong Modern Oral growth (gross sales +149% YoY), raised Modern Oral guidance, maintained EBITDA guidance, and continues investing in sales force, US manufacturing, and PMTA progress amid shelf reset lead times.','tone':{'mgmt':0.5,'mgmt_rationale':'Management highlights strong execut
- **2026 Q1:** TPB Q1 2026: Modern Oral (nicotine pouches) surges 167% gross/133% net YoY, now 42% of revenue; raised FY26 Modern Oral guidance; investing $80-105M in sales/marketing; EBITDA guide $70-90M; Louisville facility progressing; TKO partnership expanding.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Managem
- **2025 Q4:** TPB Q4 revenue rose 29% to $121M driven by Modern Oral (FRE/ALP) growth; 2026 Modern Oral net revenue guidance $180-190M; heavy investment in distribution, manufacturing, sales force; ALP brick-and-mortar launch Q2 ahead of schedule.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights st
- **2025 Q3:** TPB Q3 revenue +31% to $119M, Modern Oral +628% to $36.7M; raised FY25 EBITDA guidance to $115-120M and Modern Oral sales to $125-130M; onshoring manufacturing H1 2026, sales force doubling ahead of schedule.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlighted better-than-expected resul
- **2025 Q2:** TPB Q2 revenue +25% to $116.6M, Modern Oral 26% of sales; raised EBITDA guidance to $110-114M and pouch sales to $100-110M; white pouch sales up 8x YoY; investing in sales force doubling and US manufacturing. Tariff mitigation via inventory, supplier negotiations, price hikes. ALP retail rollout ear
- **2025 Q1:** TPB Q1 2025 beat expectations with 28% revenue growth, strong white nicotine pouch sales, raised modern oral guidance and reaffirmed EBITDA outlook while investing in sales, marketing and potential U.S. manufacturing.
- **2024 Q4:** TPB posted Q4 2024 revenue up 13% to $93.7M and adjusted EBITDA up 5%, launched modern oral brands Free and Out, and set 2025 adjusted EBITDA guidance of $108‑113M amid mix‑driven margin pressure and regulatory uncertainty.
- **2024 Q3:** TPB Q3 beat expectations with adj. EBITDA +11% to $27.2M; raised FY24 guidance to $101-103M; Zig-Zag +6%, Stoker's +12%, FRE sales quadrupled to ~$5M; expanding nicotine strengths and cigar opportunity highlighted.','tone':{'mgmt':0.7,'mgmt_rationale':'Management raised full-year EBITDA guidance, hi

## Theme arcs

- **Modern Oral (white nicotine pouch) growth** (improving): YoY sales rose 8‑10x, revenue share grew to >40%
- **EBITDA guidance trajectory** (improving): Guidance lifted each year from FY24 to FY26
- **Margin pressure from product mix** (deteriorating): Mix‑driven gross margin decline noted Q4 2024
- **Margin recovery** (improving): Gross margin rose to 57.1% in Q2 2025
- **Regulatory uncertainty** (new): FDA nicotine‑level rules and PMTA timing flagged Q4 2024
- **Regulatory risk** (resolved): No new regulatory fears after Q1 2025
- **Tariff exposure** (new): $5‑7M cost from 10% tariff cited Q1 2025
- **Tariff mitigation** (improving): Inventory, supplier negotiations, price hikes reduced impact Q2 2025
- **Sales force expansion** (new): Doubling effort announced Q1 2025, ahead of schedule by Q3 2025
- **US manufacturing/on‑shoring** (new): Exploration and investment began Q1 2025, on‑track H1 2026

## Fear persistence

- **Regulatory** [recurring]: FDA nicotine caps and PMTA timing flagged Q4 2024, Q1 2025
- **Margin pressure (mix)** [recurring]: Mix‑driven gross margin decline noted Q4 2024
- **Currency/FX** [recurring]: CAD volatility Q4 2024, euro strength Q1 2025
- **Distribution (slotting, planogram)** [recurring]: Slotting fees and slower c‑store cycles Q4 2024
- **Competitive intensity** [recurring]: Modern oral competition highlighted Q4 2024, Q1 2025
- **Tariff exposure** [recurring]: 10% tariff cost $5‑7M Q1 2025
- **Supply chain/on‑shoring risk** [recurring]: Potential need for US production Q1 2025
- **Regulatory** [resolved]: No new regulatory fears after Q1 2025
- **Margin pressure** [resolved]: Margin concerns not reiterated after Q2 2025
- **Currency** [resolved]: FX headwinds not mentioned after Q1 2025

## Guidance path

2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:raised → 2025 Q2:raised → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/TPB`